1. 平台首页
  2. 国际专利信息
  • 专利标题:   Medicinal composition for preventing or treating chronic kidney disease caused by kidney fibrosis including end-stage kidney disease, diabetic nephropathy and non-diabetic chronic kidney disease comprises graphene quantum dots.
  • 专利号:   KR2277665-B1, WO2021157818-A1, CN115397437-A, EP4101456-A1, US2023055621-A1, JP2023512960-W
  • 发明人:   HONG B H, LEE J P, YANG S H, LI L, JUHEE K, HOON K D, PARK J B, KIM J, KIM D, PIAO Z, YANG S, LEE J, HONG B
  • 专利权人:   BIOGRAPHENE INC, UNIV SEOUL NAT R DB FOUND, SNU R DB FOUND, BIOGRAPHENE INC, UNIV SEOUL NAT R DB FOUND, UNIV SEOUL NAT R DB FOUND, BIOGRAPHENE INC
  • 国际专利分类:   A61K033/44, A61P013/12, B82Y030/00, B82Y005/00
  • 专利详细信息:   KR2277665-B1 15 Jul 2021 A61K-033/44 202161 Pages: 35
  • 申请详细信息:   KR2277665-B1 KR013989 05 Feb 2020
  • 优先权号:   KR013989, CN80095781

▎ 摘　　要

NOVELTY - Medicinal composition comprises graphene quantum dots. USE - The medicinal composition is useful for preventing or treating chronic kidney disease caused by kidney fibrosis including end-stage kidney disease (ESKD), diabetic nephropathy (DN), immunoglobulin A nephropathy (IgAN), HIV-associated nephropathy, non-diabetic chronic kidney disease, focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and/or xanthine oxidase deficiency (all claimed). ADVANTAGE - The medicinal composition suppresses the expression of fibronectin, collagen 1a1, Bax, TGF- beta 1, Smad2/3 and alpha -SMA, and inhibit renal fibrosis by reducing and increasing the expression of E-cadherin and Smad7.